Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.74 |
| ▸ | STK10 | O94804 | 2/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.74 |
| ▸ | RET | P07949 | 2/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.74 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.74 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.74 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
| ▸ | HCK | P08631 | 1/20 | 0.74 |
| ▸ | KIT | P10721 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912166 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL2263514 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL18825560 | 1.00 | KDR (0.74) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Alanine SCHEMBL2729838 | 0.97 | CYP3A4 (0.73) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL29354510 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227111 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL1227534 | 0.85 | KDR (0.83) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227589 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| Brivanib SCHEMBL1227112 | 0.85 | KDR (1.00) | KDRCYP3A4FGFR1KCNH2STK10 | |
| SCHEMBL17377930 | 0.85 | CYP3A4 (0.76) | KDRCYP3A4FGFR1KCNH2STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110785187-B | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117203223-A | Lymphocyte targeting lentiviral vectors | 凯洛尼亚疗法有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117122707-A | combination therapy | 意大利国际先进加速器应用有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117098776-A | Use of anti-TGF-beta antibodies and other therapeutic agents for the treatment of proliferative diseases | 诺华股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117015396-A | Compositions and methods for treating cancer with chimeric TIM receptors in combination with poly (ADP-ribose) polymerase inhibitors | 森罗治疗公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116390936-A | Chimeric TIM receptors and uses thereof | 森罗治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116096862-A | ZBTB32 inhibitors and uses thereof | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116059344-A | Antibodies that specifically bind to PD-1 and uses thereof | 詹森生物科技公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916199-A | Dosing regimens comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives | 诺华股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-112203725-A | BCMA chimeric antigen receptors and uses thereof | 诺华股份有限公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-111386284-A | Chimeric phagocytic receptor molecules and methods of use | 森罗治疗公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-111139256-A | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-105358576-B | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptors | 诺华股份有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-110831967-A | IL-1 β binding antibodies for the treatment of cancer | 诺华股份有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110799218-A | Antibody conjugates comprising STING agonists | 诺华股份有限公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-110785187-A | Antibody molecules against CD73 and uses thereof | 诺华股份有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110678183-A | Antibody conjugates comprising TOLL-like receptor agonists and combination therapies | 诺华股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10399972-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180305352-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399972-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH3B, IDH2 | KDR 2191/4885CYP3A4 339/4885FGFR1 699/4885 |
| US-20180305352-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3B, IDH3A, IDH2 | KDR 2341/4885CYP3A4 511/4885FGFR1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.